| Market Capitalization (Millions $) |
1,308 |
| Shares
Outstanding (Millions) |
276 |
| Employees |
202 |
| Revenues (TTM) (Millions $) |
286 |
| Net Income (TTM) (Millions $) |
28 |
| Cash Flow (TTM) (Millions $) |
-191 |
| Capital Exp. (TTM) (Millions $) |
10 |
Mannkind Corporation
Mannkind Corporation is a biopharmaceutical company that operates in the United States. The company is dedicated to the development and commercialization of therapeutic products for patients with various medical conditions. Specifically, Mannkind Corporation focuses on developing therapeutic products for the treatment of pulmonary arterial hypertension, diabetes and cancer.
One of the main products developed by Mannkind Corporation is Afrezza, a rapid-acting insulin inhalation powder that is used to treat diabetes. Afrezza is an inhalable insulin that works faster than traditional insulin injections and does not require a needle. This product is patented and provides a unique approach to the treatment of diabetes.
Apart from Afrezza, Mannkind Corporation has a number of other products in development. For pulmonary arterial hypertension, the company is developing TRE-Xi, an inhaled treatment that targets the smooth muscle cells in the pulmonary arteries. Additionally, Mannkind Corporation is also developing new technology for the delivery of inhaled drugs, which is known as the Technosphere platform technology. This proprietary platform allows for the delivery of drugs using inhalation and offers enhanced product performance and increased stability.
The company has also established various collaborations with other pharmaceutical companies to develop and commercialize its products. For instance, Mannkind Corporation has a co-promotion agreement with Sanofi-Aventis for the promotion of Afrezza globally. Similarly, the company has also entered into partnerships with United Therapeutics to develop therapies for the treatment of pulmonary arterial hypertension.
Mannkind Corporation was founded in 1991 and is headquartered in California. The company has a workforce of approximately 200 employees and has a market capitalization of approximately $255 million USD. Mannkind Corporation is listed on the NASDAQ stock exchange under the ticker symbol MNKD.
Company Address: 1 Casper Street Danbury 6810 CT
Company Phone Number: 661-5000 Stock Exchange / Ticker: NASDAQ MNKD
|
9.33% 